Key result
Computed tomography imaging provides a detailed evaluation of lung architecture to assess the extent, severity, and progression of emphysema and airways disease in alpha-1 antitrypsin deficiency.
Why the study?
What is the role of computed tomography in assessing pulmonary disease progression and therapeutic interventions in Alpha-1 Antitrypsin Deficiency?
What is the role of computed tomography in assessing pulmonary disease progression and therapeutic interventions in Alpha-1 Antitrypsin Deficiency?
Quantitative CT imaging offers a more detailed and accurate assessment of lung architecture and disease progression in Alpha-1 Antitrypsin Deficiency compared to traditional pulmonary function tests.
Alpha-1 antitrypsin deficiency (AATD) is characterized by low serum levels of or dysfunctional alpha-1 proteinase inhibitor. In the lung parenchyma, this results in a loss of protection against the activity of serine proteases, particularly neutrophil elastase. The resultant imbalance in protease and antiprotease activity leads to an increased risk for the development of early-onset emphysema and COPD. As in traditional smoke-related COPD, the assessment of the severity and disease progression of lung disease in AATD is conventionally based on lung function; however, pulmonary function tests are unable to discriminate between emphysema and airways disease, the two hallmark pathologic features of COPD. CT imaging has been used as a tool to further characterize lung structure and evaluate therapeutic interventions in AATD-related COPD. Moreover, recent advances in quantitative CT have significantly improved our assessment of the lung architecture, which has provided investigators and clinicians with a more detailed evaluation of the extent and severity of emphysema and airways disease in AATD. In addition, serial CT imaging measures are becoming increasingly important, as they provide a tool to monitor emphysema progression. This review describes the principles of CT technology and the role of CT imaging in assessing pulmonary disease progression in AATD, including the effect of therapeutic interventions.
No takes yet. Share an insight, caveat, or question.
Campos et al. (2017) conducted a review in Alpha-1 antitrypsin deficiency (AATD). Computed Tomography (CT) imaging was evaluated. Computed tomography imaging provides a detailed evaluation of lung architecture to assess the extent, severity, and progression of emphysema and airways disease in alpha-1 antitrypsin deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: